Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 289 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Low Risk Acute Graft-versus-host Disease Clear all
Withdrawn Not applicable Interventional

A Strategy to Improve Implementation of LTVV for Patients w/ ARDS

NCT03051139
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Multi-component LTVV implementation strategy
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

NCT00671879
View directory record Official record
Conditions
Lower Back Pain
Interventions
Carisoprodol SR 700 mg, Carisoprodol SR 500 mg, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
73
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Hueytown, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 17, 2026, 6:56 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.

NCT05721027
View directory record Official record
Conditions
Radiculopathy, Lumbosacral Region, Back Pain With Radiation, Low Back Pain
Interventions
Ibuprofen 400 mg, Dexamethasone Oral, Educational Intervention
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

NCT00926731
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
AZD1152, LDAC (low dose cytosine arabinoside)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Not applicable Interventional

Impact of a Decision Aid on Patient Decision Making in Emergency Department Chest Pain Patients

NCT01077037
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Decision Aid
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 4 Interventional Results available

Volume Versus Concentration: Clinical Effectiveness of Single Shot Quadrates Lumborum Block Using Either a High Volume/Low Concentration or Low Volume/High Concentration Injectate for Total Hip Arthroplasty.

NCT04259645
View directory record Official record
Conditions
Acute Pain
Interventions
Drug: Bupivacaine 0.375% 20 mL, Drug: Bupivacaine 0.375% diluted to 0.1875%
Drug
Lead sponsor
Anna Uskova
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Effect of Lithium Therapy on Long COVID Symptoms

NCT05618587
View directory record Official record
Conditions
Long COVID
Interventions
Lithium, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 17, 2026, 6:56 AM EDT
Withdrawn Not applicable Interventional

The Effect of Low-Intensity Blood Flow Restriction Therapy on the Management of Acute Ankle Sprains

NCT05596162
View directory record Official record
Conditions
Ankle Sprain 1St Degree, Ankle Sprain 2Nd Degree, Musculoskeletal Injury
Interventions
Blood Flow Restriction Therapy, Standard Physical Therapy
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

NCT00952588
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
AZD1152, LDAC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Not applicable Interventional Results available

Usability of a Multimodal External Neuromodulatory Device to Relieve Acute Low Back Pain

NCT04494841
View directory record Official record
Conditions
Low Back Pain, Low Back Sprain, Low Back Pain, Recurrent
Interventions
Duotherm VibraCool Back Device
Device
Lead sponsor
MMJ Labs LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 17, 2026, 6:56 AM EDT
Not listed Not applicable Interventional

Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates

NCT02445040
View directory record Official record
Conditions
Respiratory Distress Syndrome In Premature Infants
Interventions
Babylog VN500 in HFOV Mode
Device
Lead sponsor
Draeger Medical Systems, Inc.
Industry
Eligibility
23 Weeks to 30 Weeks
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
14
States / cities
Little Rock, Arkansas • San Diego, California • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 17, 2026, 6:56 AM EDT
Completed No phase listed Observational

Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia

NCT00993135
View directory record Official record
Conditions
Leukemia, Renal Toxicity
Interventions
methotrexate, medical chart review, assessment of therapy complications
Drug · Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 17, 2026, 6:56 AM EDT
Recruiting No phase listed Observational

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade, Myelodysplastic Syndrome With Low-grade Lesions, IgG Monoclonal Gammopathy of Uncertain Significance, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 17, 2026, 6:56 AM EDT
Terminated Phase 3 Interventional Results available

Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

NCT01366612
View directory record Official record
Conditions
Myeloid Malignancies, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Disorders, Myelodysplastic Syndrome
Interventions
Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose), Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 1Phase 2 Interventional

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

NCT00006251
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
total-body irradiation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, nonmyeloablative allogeneic hematopoietic stem cell transplantation, donor lymphocytes, peripheral blood stem cell transplantation, laboratory biomarker analysis
Radiation · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Tolperisone in Acute Muscle Spasm of the Back

NCT03802565
View directory record Official record
Conditions
Back Pain, Acute Pain, Back Spasm Upper Back, Back Strain, Muscle Cramp, Muscle Spasm, Low Back Pain
Interventions
Tolperisone, Placebo
Drug
Lead sponsor
Neurana Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
43
States / cities
Huntsville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 17, 2026, 6:56 AM EDT
Completed No phase listed Observational

"SVEAT" Chest Pain Scoring System

NCT03511430
View directory record Official record
Conditions
Chest Pain
Interventions
Not listed
Lead sponsor
University of Nevada, Reno
Other
Eligibility
24 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 17, 2026, 6:56 AM EDT
Terminated Not applicable Interventional

Intracutaneous Sterile Water Injections for Acute Low Back Pain in the Emergency Department

NCT04240483
View directory record Official record
Conditions
Low Back Pain
Interventions
Intracutaneous sterile water injections (ISWI) group, Intracutaneous dry injections (IDI) group
Other
Lead sponsor
Lindsey schmelzer
Federal
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 1Phase 2 Interventional

BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.

NCT00252200
View directory record Official record
Conditions
Acute Kidney Failure
Interventions
Neseritide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Itacitinib for Low Risk GVHD

NCT03846479
View directory record Official record
Conditions
Low Risk Acute Graft-versus-host Disease, Graft-versus-host-disease, GVHD
Interventions
Itacitinib
Drug
Lead sponsor
John Levine
Other
Eligibility
12 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 17, 2026, 6:56 AM EDT
Terminated Not applicable Interventional

Acute Lung Injury Ventilator Evaluation (ALIVE)

NCT01901354
View directory record Official record
Conditions
Acute Lung Injury, Adult Respiratory Distress Syndrome
Interventions
Low-tidal-volume ventilation, Airway Pressure Release Ventilation (APRV)
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 17, 2026, 6:56 AM EDT
Recruiting Phase 2 Interventional

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT03586609
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Cladribine, Cytarabine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 6:56 AM EDT
Active, not recruiting Phase 2 Interventional

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

NCT05303792
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin
Drug · Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
50 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
71
States / cities
Birmingham, Alabama • Irvine, California • Orange, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

NCT00492856
View directory record Official record
Conditions
Leukemia
Interventions
mercaptopurine, methotrexate, tretinoin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
210
States / cities
Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 17, 2026, 6:56 AM EDT